Mellon wins prestigious Charing Cross Dragons’ Den Innovation Showcase competition.
London, 27 April 2016
A great recognition of the merits of the Switch suturing device by the international vascular surgery community as Mellon wins the prestigious 2016 Charing Cross Dragon’s Den Innovation Showcase competition.
The Charing Cross Innovation Showcase is dedicated to highlighting what it takes for innovative ideas in the vascular and endovascular disciplines to thrive. It brings together physicians, leading industry experts, medtech investors and start-up companies focused on improving vascular disease management. It provides a glimpse into the future regarding emerging technologies and next generation devices that address current unmet therapeutic needs.
The panel – consisting of Stephen Greenhalgh (Managing Director at BIBA Medical), Chas Taylor (Medical Device Entrepreneur), Jason Field (Global Marketing Leader at W. L. Gore & Associates), Daveen Chopra (VP and General Manager, Medtronic Aortic), and Bob Mitchell (President Endologix) – unanimously voted the Switch suturing device as winner of this years’ Dragons’ Den out of a total of 10 pre-selected contestants.
About Charing Cross International Symposium:
The Charing Cross International Symposium (CX), first took place in 1978 at Charing Cross Hospital, Hammersmith, London and has by now become the longest running vascular and endovascular symposium in Europe and one of the largest in the world.
London (UK) has been the host city of CX ever since. Until 1998, the symposium was held at Charing Cross Hospital, and between 1999 and 2012 at Imperial College. In 2013, it moved to National Hall, Olympia, and in 2014 to Olympia Grand.
The first CX had 100 attendees. In 2015, the Charing Cross International Symposium had a record number of 4,367 participants, from 79 countries, making it a leading global event.
The Charing Cross Symposium raises vascular and endovascular controversies so that a world-class faculty challenges the available evidence in order to reach a consensus after discussion with an expert audience.